|Bid||0.51 x 1200|
|Ask||0.53 x 3800|
|Day's Range||0.50 - 0.56|
|52 Week Range||0.36 - 3.44|
|PE Ratio (TTM)||-0.81|
|Earnings Date||May 9, 2017 - May 15, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||4.00|
LOS ANGELES, April 28, 2017 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has priced a public offering of approximately 30 million shares of its common stock at a purchase price of $0.50 per share, for gross proceeds of approximately $15 million. H.C. Wainwright & Co. is acting as exclusive placement agent for the offering. After deducting the placement agent's fees and other estimated offering expenses payable by CytRx, the net proceeds to CytRx are anticipated to be approximately $13.8 million. CytRx intends to use the net proceeds from the offering for working capital and general corporate purposes, including clinical and regulatory activities, new drug discovery activities, and possible future strategic transactions.
LOS ANGELES, April 27, 2017 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology today announced a proposed public offering of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be consummated, or as to the actual size or terms of the offering. H.C. Wainwright & Co. is acting as exclusive placement agent for the offering.
These ten penny stocks trading on U.S. public exchanges could gain substantial ground in April 2017 and the coming months.